New class of alkynyl glycoside analogues as tyrosinase inhibitors
Related Experiment Video
Updated: Dec 18, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Natthiya Saehlim1, Anan Athipornchai2, Uthaiwan Sirion2
1Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Burapha University, Sangesook, ChonBuri 20131, Thailand.
Abstract:
A new series of alkynyl glycoside analogues were designed and synthesized from cheap and a commercially available sugar by introduction of various alkynyl and alkyl groups at C-1 and C-6 positions of the sugar ring. The inhibitory abilities of alkynyl glycosides were investigated in vitro on mushroom tyrosinase for the catalysis of l-Tyrosine and l-DOPA as substrates and comparing with arbutin and kojic acid. Non-terminal alkyne compound 2d showed excellent tyrosinase inhibitory activity (IC50 54.0 μM) against l-Tyrosine comparable to arbutin (IC50 1.46 mM) while 2b exhibited potent activities (IC50 34.3 μM) against L-DOPA higher than kojic acid (IC50 0.11 mM) and arbutin (IC50 13.3 mM). Kinetic studies revealed that compound 2d was a non-competitive inhibitor with the best Ki value of 21 μM and formed an irreversible receptor complex with mushroom tyrosinase. The SARs results showed that the type of alkyne and alkyl groups at position C-6 on sugar and the stereoisomer played an important role in determining their inhibitory activities. The potent activity of alkynyl glycosides identified in this study highlight the importance of this scaffold and these compounds are very modestly potent to the development of new class for tyrosinase inhibitor.
More Related Videos
Related Concept Videos
Oral Hypoglycemic Agents: Sulfonylureas
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Enzyme Inhibition

